t-cell bispecific antibody targeting intracellular wt1 in aml
Published 4 years ago • 256 plays • Length 1:04Download video MP4
Download video MP3
Similar videos
-
2:22
t-cell bispecifics in aml: ongoing challenges and future outlooks
-
2:30
aml: targeting wilms' tumor 1 with wt1-tcb
-
2:36
a cd38-targeting bispecific antibody in the treatment of r/r t-all
-
3:01
t-cell engaging antibodies: novel combinations to overcome resistance
-
2:25
current and emerging immune therapies in al amyloidosis: updates on hbi0101 & bispecifics
-
4:15
bispecific antibodies in multiple myeloma: teclistamab, talquetamab, and cevostamab
-
5:15
the promise of immunotherapies in t-cell lymphoma
-
2:41
cell avidity as a predictor of t-cell efficacy
-
13:47
latest news in myeloma: mrd, bites, and car t-cells
-
2:27
v2019 ebsensor & ebketone blood glucose/ketone meter - instruction video | ebmonitor® by visgeneer
-
9:57
teclistamab, a bcma × cd3 bispecific antibody, in pts with rrmm: updated phase 1 results
-
1:52
first-in-human results of the anti-bcma antibody-drug conjugate hdp-101 in r/r myeloma
-
1:41
lava-051: a novel bispecific t-cell engager for r/r hematological malignancies
-
5:29
targeting cd1c-expressing leukemia with engineered t-cells
-
3:56
autoimmune cytopenias in cll and the impact of targeted therapies
-
1:01
an update on the phase i trial of bms-986393, a novel gprc5d-targeted car-t, in r/r myeloma
-
2:21
targeting b-cell receptor signaling with btk degraders to treat cll
-
0:16
activated t cell attacks a cancer cell
-
1:47
abnormal serum immunofixation patterns following bcma car-t in multiple myeloma
-
21:32
bispecific antibodies for t‐cell redirection therapy
-
1:26
prognostic and predictive biomarkers in cll and their potential in guiding treatment decisions
-
6:15
how to manage and report aes associated with bispecific antibody treatment in myeloma